Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH

Posted: December 26, 2022 at 12:12 am

NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study

Read the original post:
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH

Related Posts